Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma : A MASK-air study
Copyright © 2023 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved..
INTRODUCTION: Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA.
MATERIALS AND METHODS: We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day.
RESULTS: In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001).
CONCLUSIONS: In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Pulmonology - (2023) vom: 03. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sousa-Pinto, B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adherence |
|---|
| Anmerkungen: |
Date Revised 05.08.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.pulmoe.2023.07.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360432123 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360432123 | ||
| 003 | DE-627 | ||
| 005 | 20231226083012.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pulmoe.2023.07.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360432123 | ||
| 035 | |a (NLM)37543524 | ||
| 035 | |a (PII)S2531-0437(23)00130-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sousa-Pinto, B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma |b A MASK-air study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a INTRODUCTION: Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA | ||
| 520 | |a MATERIALS AND METHODS: We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day | ||
| 520 | |a RESULTS: In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001) | ||
| 520 | |a CONCLUSIONS: In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adherence | |
| 650 | 4 | |a Asthma | |
| 650 | 4 | |a Formoterol | |
| 650 | 4 | |a Inhaled corticosteroids | |
| 650 | 4 | |a Long-acting-β2 agonist | |
| 700 | 1 | |a Louis, R |e verfasserin |4 aut | |
| 700 | 1 | |a Anto, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Amaral, R |e verfasserin |4 aut | |
| 700 | 1 | |a Sá-Sousa, A |e verfasserin |4 aut | |
| 700 | 1 | |a Czarlewski, W |e verfasserin |4 aut | |
| 700 | 1 | |a Brussino, L |e verfasserin |4 aut | |
| 700 | 1 | |a Canonica, G W |e verfasserin |4 aut | |
| 700 | 1 | |a Chaves Loureiro, C |e verfasserin |4 aut | |
| 700 | 1 | |a Cruz, A A |e verfasserin |4 aut | |
| 700 | 1 | |a Gemicioglu, B |e verfasserin |4 aut | |
| 700 | 1 | |a Haahtela, T |e verfasserin |4 aut | |
| 700 | 1 | |a Kupczyk, M |e verfasserin |4 aut | |
| 700 | 1 | |a Kvedariene, V |e verfasserin |4 aut | |
| 700 | 1 | |a Larenas-Linnemann, D E |e verfasserin |4 aut | |
| 700 | 1 | |a Okamoto, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Ollert, M |e verfasserin |4 aut | |
| 700 | 1 | |a Pfaar, O |e verfasserin |4 aut | |
| 700 | 1 | |a Pham-Thi, N |e verfasserin |4 aut | |
| 700 | 1 | |a Puggioni, F |e verfasserin |4 aut | |
| 700 | 1 | |a Regateiro, F S |e verfasserin |4 aut | |
| 700 | 1 | |a Romantowski, J |e verfasserin |4 aut | |
| 700 | 1 | |a Sastre, J |e verfasserin |4 aut | |
| 700 | 1 | |a Scichilone, N |e verfasserin |4 aut | |
| 700 | 1 | |a Taborda-Barata, L |e verfasserin |4 aut | |
| 700 | 1 | |a Ventura, M T |e verfasserin |4 aut | |
| 700 | 1 | |a Agache, I |e verfasserin |4 aut | |
| 700 | 1 | |a Bedbrook, A |e verfasserin |4 aut | |
| 700 | 1 | |a Becker, S |e verfasserin |4 aut | |
| 700 | 1 | |a Bergmann, K C |e verfasserin |4 aut | |
| 700 | 1 | |a Bosnic-Anticevich, S |e verfasserin |4 aut | |
| 700 | 1 | |a Bonini, M |e verfasserin |4 aut | |
| 700 | 1 | |a Boulet, L-P |e verfasserin |4 aut | |
| 700 | 1 | |a Brusselle, G |e verfasserin |4 aut | |
| 700 | 1 | |a Buhl, R |e verfasserin |4 aut | |
| 700 | 1 | |a Cecchi, L |e verfasserin |4 aut | |
| 700 | 1 | |a Charpin, D |e verfasserin |4 aut | |
| 700 | 1 | |a de Blay, F |e verfasserin |4 aut | |
| 700 | 1 | |a Del Giacco, S |e verfasserin |4 aut | |
| 700 | 1 | |a Ivancevich, J C |e verfasserin |4 aut | |
| 700 | 1 | |a Jutel, M |e verfasserin |4 aut | |
| 700 | 1 | |a Klimek, L |e verfasserin |4 aut | |
| 700 | 1 | |a Kraxner, H |e verfasserin |4 aut | |
| 700 | 1 | |a Kuna, P |e verfasserin |4 aut | |
| 700 | 1 | |a Laune, D |e verfasserin |4 aut | |
| 700 | 1 | |a Makela, M |e verfasserin |4 aut | |
| 700 | 1 | |a Morais-Almeida, M |e verfasserin |4 aut | |
| 700 | 1 | |a Nadif, R |e verfasserin |4 aut | |
| 700 | 1 | |a Niedoszytko, M |e verfasserin |4 aut | |
| 700 | 1 | |a Papadopoulos, N G |e verfasserin |4 aut | |
| 700 | 1 | |a Papi, A |e verfasserin |4 aut | |
| 700 | 1 | |a Patella, V |e verfasserin |4 aut | |
| 700 | 1 | |a Pétré, B |e verfasserin |4 aut | |
| 700 | 1 | |a Rivero Yeverino, D |e verfasserin |4 aut | |
| 700 | 1 | |a Robalo Cordeiro, C |e verfasserin |4 aut | |
| 700 | 1 | |a Roche, N |e verfasserin |4 aut | |
| 700 | 1 | |a Rouadi, P W |e verfasserin |4 aut | |
| 700 | 1 | |a Samolinski, B |e verfasserin |4 aut | |
| 700 | 1 | |a Savouré, M |e verfasserin |4 aut | |
| 700 | 1 | |a Shamji, M H |e verfasserin |4 aut | |
| 700 | 1 | |a Sheikh, A |e verfasserin |4 aut | |
| 700 | 1 | |a Suppli Ulrik, C |e verfasserin |4 aut | |
| 700 | 1 | |a Usmani, O S |e verfasserin |4 aut | |
| 700 | 1 | |a Valiulis, A |e verfasserin |4 aut | |
| 700 | 1 | |a Yorgancioglu, A |e verfasserin |4 aut | |
| 700 | 1 | |a Zuberbier, T |e verfasserin |4 aut | |
| 700 | 1 | |a Fonseca, J A |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, E M |e verfasserin |4 aut | |
| 700 | 1 | |a Bousquet, J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pulmonology |d 2017 |g (2023) vom: 03. Aug. |w (DE-627)NLM278404561 |x 2531-0437 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:03 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pulmoe.2023.07.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 03 |c 08 | ||